Macrophage-Mediated Delivery of Multifunctional Nanotherapeutics for Synergistic Chemo–Photothermal Therapy of Solid Tumors
Source abstract
Abstract
Although great efforts have been undertaken to develop a nanoparticle-based drug delivery system (DDS) for the treatment of solid tumors, the therapeutic outcomes are still limited. Immune cells, which possess an intrinsic ability to phagocytose nanoparticles and are recruited by tumors, can be exploited to deliver nanotherapeutics deep inside the tumors. Photothermal therapy using near-infrared light is a promising noninvasive approach for solid tumor ablation, especially when combined with chemotherapy. In this study, we design and evaluate a macrophage-based, multiple nanotherapeutics DDS, involving the phagocytosis by macrophages of both small-sized gold nanorods and anticancer drug-containing nanoliposomes. The aim is to treat solid tumors, utilizing the tumor-infiltrating properties of macrophages with synergistic photothermal-chemotherapy. Using a 3D cancer spheroid as an in vitro solid tumor model, we show that tumor penetration and coverage of the nanoparticles are both markedly enhanced when the macrophages are used. In addition, in vivo experiments involving both local and systemic administrations in breast tumor-bearing mice demonstrate that the proposed DDS can effectively target and kill the tumors, especially when the synergistic therapy is used. Consequently, this immune cell-based theranostic strategy may represent a potentially important advancement in the treatment of solid tumors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Mechanical Engineering, Chonnam National University, 77 Yongbong-ro, Buk-gu, Gwangju 61186, Korea
Korea Institute of Medical Microrobotics, 43-26, Cheomdangwagi-ro 208-beon-gil, Buk-gu, Gwangju 61011, Korea
Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland 21205, United States
Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States
Funding
Korea Health Industry Development Institute
References (53)
Show source-provided references
1. 10.1126/science.109583310.1126/science.1095833 ↗
2. 10.1016/j.jconrel.2014.12.03010.1016/j.jconrel.2014.12.030 ↗
3. 10.1016/j.biomaterials.2012.01.03610.1016/j.biomaterials.2012.01.036 ↗
4. 10.1016/j.msec.2019.11030310.1016/j.msec.2019.110303 ↗
5. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
6. 10.1021/nl072209h10.1021/nl072209h ↗
7. 10.1111/j.1349-7006.2003.tb01395.x10.1111/j.1349-7006.2003.tb01395.x ↗
8. 10.3390/pharmaceutics1004019310.3390/pharmaceutics10040193 ↗
9. 10.1063/1.243145410.1063/1.2431454 ↗
10. 10.1063/1.307965510.1063/1.3079655 ↗
11. 10.1038/nnano.2016.13710.1038/nnano.2016.137 ↗
12. 10.1038/4581121a10.1038/4581121a ↗
13. 10.1021/nn501130410.1021/nn5011304 ↗
14. 10.1177/027836490810092410.1177/0278364908100924 ↗
15. 10.1021/acsnano.7b0320710.1021/acsnano.7b03207 ↗
16. 10.1021/acsnano.7b0208210.1021/acsnano.7b02082 ↗
17. 10.1016/j.snb.2016.09.07610.1016/j.snb.2016.09.076 ↗
18. 10.1038/srep2871710.1038/srep28717 ↗
19. 10.1016/j.biomaterials.2015.09.03810.1016/j.biomaterials.2015.09.038 ↗
20. 10.1002/bit.2527010.1002/bit.25270 ↗
21. 10.1016/j.biomaterials.2012.02.02210.1016/j.biomaterials.2012.02.022 ↗
22. 10.1016/j.biomaterials.2015.08.03310.1016/j.biomaterials.2015.08.033 ↗
23. 10.1038/nnano.2014.6210.1038/nnano.2014.62 ↗
24. 10.1016/j.jconrel.2015.01.03910.1016/j.jconrel.2015.01.039 ↗
25. 10.1016/j.colsurfb.2017.03.00810.1016/j.colsurfb.2017.03.008 ↗
26. 10.1016/j.colsurfb.2018.10.01310.1016/j.colsurfb.2018.10.013 ↗
27. 10.1073/pnas.161930211410.1073/pnas.1619302114 ↗
28. 10.1002/anie.20150611510.1002/anie.201506115 ↗
29. 10.1039/c5tb00560d10.1039/c5tb00560d ↗
30. 10.1039/c5nr06501a10.1039/c5nr06501a ↗
31. 10.1016/j.jconrel.2009.10.00210.1016/j.jconrel.2009.10.002 ↗
32. 10.1016/j.apsb.2017.09.00510.1016/j.apsb.2017.09.005 ↗
33. 10.1016/j.jconrel.2017.03.03510.1016/j.jconrel.2017.03.035 ↗
34. 10.1039/b607071j10.1039/b607071j ↗
35. 10.1039/c5nr07796f10.1039/c5nr07796f ↗
36. 10.1002/adma.20180555710.1002/adma.201805557 ↗
37. 10.5483/bmbrep.2013.46.3.03610.5483/bmbrep.2013.46.3.036 ↗
38. 10.1172/jci5964310.1172/jci59643 ↗
39. 10.1189/jlb.071040910.1189/jlb.0710409 ↗
40. 10.1093/cvr/cvu02510.1093/cvr/cvu025 ↗
41. 10.18632/oncotarget.211010.18632/oncotarget.2110 ↗
42. 10.1007/s12032-010-9638-510.1007/s12032-010-9638-5 ↗
43. 10.1021/nn201010q10.1021/nn201010q ↗
44. 10.1038/8668410.1038/86684 ↗
45. 10.2147/ijn.s2676610.2147/ijn.s26766 ↗
46. 10.18632/oncotarget.946410.18632/oncotarget.9464 ↗
47. 10.1002/adma.20110471410.1002/adma.201104714 ↗
48. 10.1038/ncomms900910.1038/ncomms9009 ↗
49. 10.1021/la301387p10.1021/la301387p ↗
50. 10.1016/j.jconrel.2013.11.01610.1016/j.jconrel.2013.11.016 ↗
51. 10.1021/bc100354m10.1021/bc100354m ↗
52. 10.1021/nn401717910.1021/nn4017179 ↗
53. 10.1080/10717544.2018.150283910.1080/10717544.2018.1502839 ↗